Cargando…

Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study

BACKGROUND AND PURPOSE: Acamprosate is an anti‐craving drug used for the pharmacotherapy of alcohol use disorder (AUD). However, only some patients achieve optimal therapeutic outcomes. This study was designed to explore differences in metabolomic profiles between patients who maintained sobriety an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Ming‐Fen, Zhang, Cheng, Wei, Lixuan, Zhang, Lingxin, Moon, Irene, Geske, Jennifer R., Skime, Michelle K., Choi, Doo‐Sup, Biernacka, Joanna M., Oesterle, Tyler S., Frye, Mark A., Seppala, Marvin D., Karpyak, Victor M., Li, Hu, Weinshilboum, Richard M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177536/ https://www.ncbi.nlm.nih.gov/pubmed/35016259 http://dx.doi.org/10.1111/bph.15795

Ejemplares similares

TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response
por: Ho, Ming-Fen, et al.
Publicado: (2020)

Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder
por: Ho, Ming-Fen, et al.
Publicado: (2022)

Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism
por: Ho, Ming-Fen, et al.
Publicado: (2022)

Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects
por: Hinton, David J., et al.
Publicado: (2017)

PM307. Untargeted Global Metabolomics Reveals Metabolites Associated with Acamprosate Treatment Outcome
por: Ho, Ada, et al.
Publicado: (2016)

Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects
por: Nam, H W, et al.
Publicado: (2015)

Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate
por: Karpyak, V M, et al.
Publicado: (2014)

PM321. DNA Methylation Signature Associated with Abstinence in Alcoholics Treated with Acamprosate
por: Hlady, R., et al.
Publicado: (2016)

Epigenetic regulation of GABA catabolism in iPSC-derived neurons: The molecular links between FGF21 and histone methylation
por: Ho, Ming-Fen, et al.
Publicado: (2023)

Corrigendum to “Genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder” [Drug Alcohol Depend. 243 (2023) 109753]
por: Karpyak, Victor M., et al.
Publicado: (2023)

Safety and Efficacy of Acamprosate for the Treatment of Alcohol Dependence
por: Yahn, Stephanie L., et al.
Publicado: (2013)

Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study
por: Biernacka, Joanna M., et al.
Publicado: (2021)

Acamprosate: a new tool in the battle against alcohol dependence
por: Wright, Tara M, et al.
Publicado: (2006)

Role of acamprosate in sensorineural tinnitus
por: Sharma, Dinesh Kumar, et al.
Publicado: (2012)

Unusual side effects with acamprosate
por: Sidana, Ajeet Kumar, et al.
Publicado: (2007)

Rare Anaphylactic Reaction to Acamprosate in a Young Alcoholic
por: Patnaik, Asha, et al.
Publicado: (2019)

Calcium acamprosate: a triclinic polymorph
por: Maccaroni, Elisabetta, et al.
Publicado: (2011)

Associations of prodynorphin sequence variation with alcohol dependence and related traits are phenotype-specific and sex-dependent
por: Winham, Stacey J., et al.
Publicado: (2015)

Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility
por: Witkiewitz, Katie, et al.
Publicado: (2012)

Acamprosate-induced Extrapyramidal Symptoms in an Elderly Patient with Alcohol Dependence
por: Woo, Jungmin, et al.
Publicado: (2014)

Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication
por: Joyce, Jeremiah B., et al.
Publicado: (2021)

Replication of Genome Wide Association Studies of Alcohol Dependence: Support for Association with Variation in ADH1C
por: Biernacka, Joanna M., et al.
Publicado: (2013)

Deterrent Action of Acamprosate: A Case Report
por: Spoorthy, Mamidipalli Sai, et al.
Publicado: (2019)

Tinnitus treatment with acamprosate: double-blind study
por: Azevedo, Andréia A., et al.
Publicado: (2015)

Genetic variant in SLC1A2 is associated with elevated anterior cingulate cortex glutamate and lifetime history of rapid cycling
por: Veldic, Marin, et al.
Publicado: (2019)

Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2012)

Acamprosate-induced myoclonic jerks: A rare side effect
por: Soni, Puneet Kumar, et al.
Publicado: (2021)

PDYN rs2281285 Variant Association with Drinking to Avoid Emotional or Somatic Discomfort
por: Preuss, Ulrich W., et al.
Publicado: (2013)

Gender‐specific effects of comorbid depression and anxiety on the propensity to drink in negative emotional states
por: Karpyak, Victor M., et al.
Publicado: (2016)

Pharmacogenomics‐Driven Prediction of Antidepressant Treatment Outcomes: A Machine‐Learning Approach With Multi‐trial Replication
por: Athreya, Arjun P., et al.
Publicado: (2019)

Functional Role of the Polymorphic 647 T/C Variant of ENT1 (SLC29A1) and Its Association with Alcohol Withdrawal Seizures
por: Kim, Jeong-Hyun, et al.
Publicado: (2011)

Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties: Implications for Renal Acamprosate Secretion and Drug–Drug Interactions
por: Antonescu, Irina E., et al.
Publicado: (2020)

Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease
por: Hajj, Rodolphe, et al.
Publicado: (2015)

Differential SLC1A2 Promoter Methylation in Bipolar Disorder With or Without Addiction
por: Jia, Yun-Fang, et al.
Publicado: (2017)

Six-Month Outcome in Bipolar Spectrum Alcoholics Treated with Acamprosate after Detoxification: A Retrospective Study
por: Maremmani, Angelo Giovanni Icro, et al.
Publicado: (2014)

A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence
por: Kumar, Arun, et al.
Publicado: (2020)

SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function
por: Zhang, Lingxin, et al.
Publicado: (2021)

Sodium acamprosate and calcium exert additive effects on nucleus accumbens dopamine in the rat
por: Ademar, Karin, et al.
Publicado: (2022)

Hypersalivation and coarse tremors as uncommon side effects of acamprosate: A case report
por: Bhandutia, D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cubirlbpcfoj8a487oo4miqpk9